Q-omics provides the consensus-scored UBE2S profile across patient tissues and cancer cell-line models. UBE2S expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UBE2S is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, UBE2S protein abundance shows 34,897 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where UBE2S shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2S — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2S survival associations across molecular data types. UBE2S RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2S RNA expression–survival associations across cancer types. High UBE2S expression shows unfavorable associations in ACC, KIRP, KIRC, MESO, KICH and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for UBE2S RNA expression.
This table summarizes UBE2S tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for UBE2S. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2S shows higher tumor expression in HNSC, COAD, LUAD, BLCA, KIRP and LIHC. The HNSC box plot shows higher UBE2S RNA expression in tumor versus normal tissue (log2 FC = +2.282, t-test p < 0.001).
This table shows molecular features associated with UBE2S in patient tissues and cancer cell lines. In patient samples, UBE2S shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2S RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
